Skip to main content
Top
Published in: Respiratory Research 1/2009

Open Access 01-12-2009 | Research

Activated mammalian target of rapamycin is associated with T regulatory cell insufficiency in nasal polyps

Authors: Geng Xu, Jiahong Xia, Xiaoyang Hua, Han Zhou, Chuanzhao Yu, Zheng Liu, Kemin Cai, Jianbo Shi, Huabin Li

Published in: Respiratory Research | Issue 1/2009

Login to get access

Abstract

Background

Decreased infiltration of Foxp3+ T regulatory cell (Treg) is considered to be critical for the Th1/Th2 dysregulation of nasal polyps, while the cellular mechanism underlying Foxp3+ Treg insufficiency is currently not well defined.

Methods

We attempted to investigate the tissue expression of phosphorylated mammalian target of rapamycin (pmTOR) and infiltration of Foxp3+ Tregs in 28 nasal polyps and 16 controls by histological staining. We also evaluated the effects of blocking the mTOR signaling pathway with rapamycin on T cell phenotype selection and Foxp3+CD4+ Tregs expansion in a tissue culture system.

Results

Significantly increased infiltration of pmTOR+ inflammatory cells and decreased infiltration of Foxp3+CD4+ Tregs into nasal polyps was observed, with an inverse association. In the tissue culture system, we detected significantly elevated Foxp3 expression and IL-10 production, as well as an increased percentage of Foxp3+ Tregs in nasal polyps after blocking the mTOR signaling pathway with rapamycin.

Conclusion

Here we demonstrate for the first time that the mTOR signaling pathway is associated with Foxp3+ Tregs insufficiency in nasal polyps. Inhibition of the mTOR signaling pathway may be helpful for enhancement of Foxp3+ Treg expansion, as well as modulation of T cell phenotype imbalances in nasal polyps.
Literature
1.
go back to reference Meltzer EO, Hamilos DL, Hadley JA, Lanza DC, Marple BF, Nicklas RA, Adinoff AD, Bachert C, Borish L, Chinchilli VM, Danzig MR, Ferguson BJ, Fokkens WJ, Jenkins SG, Lund VJ, Mafee MF, Naclerio RM, Pawankar R, Ponikau JU, Schubert MS, Slavin RG, Stewart MG, Togias A, Wald ER, Winther B, The Rhinosinusitis Initiative: Rhinosinusitis: developing guidance for clinical trials. J Allergy Clin Immunol 2006,118(5 Suppl):S17–61.CrossRefPubMed Meltzer EO, Hamilos DL, Hadley JA, Lanza DC, Marple BF, Nicklas RA, Adinoff AD, Bachert C, Borish L, Chinchilli VM, Danzig MR, Ferguson BJ, Fokkens WJ, Jenkins SG, Lund VJ, Mafee MF, Naclerio RM, Pawankar R, Ponikau JU, Schubert MS, Slavin RG, Stewart MG, Togias A, Wald ER, Winther B, The Rhinosinusitis Initiative: Rhinosinusitis: developing guidance for clinical trials. J Allergy Clin Immunol 2006,118(5 Suppl):S17–61.CrossRefPubMed
2.
go back to reference Sánchez-Segura A, Brieva JA, Rodríguez C: T lymphocytes that infiltrate nasal polyps have a specialized phenotype and produce a mixed TH1/TH2 pattern of cytokines. J Allergy Clin Immunol 1998,102(6 pt 1):953–60.CrossRefPubMed Sánchez-Segura A, Brieva JA, Rodríguez C: T lymphocytes that infiltrate nasal polyps have a specialized phenotype and produce a mixed TH1/TH2 pattern of cytokines. J Allergy Clin Immunol 1998,102(6 pt 1):953–60.CrossRefPubMed
3.
go back to reference Miller CH, Pudiak D, Hatem F, Looney RJ: Accumulation of interferon gamma-producing TH1 helper T cells in nasal polyps. Otolaryngol Head Neck Surg 1994,111(1):51–8.CrossRefPubMed Miller CH, Pudiak D, Hatem F, Looney RJ: Accumulation of interferon gamma-producing TH1 helper T cells in nasal polyps. Otolaryngol Head Neck Surg 1994,111(1):51–8.CrossRefPubMed
4.
go back to reference Van Zele T, Claeys S, Gevaert P, Van Maele G, Holtappels G, Van Cauwenberge P, Bachert C: Differentiation of chronic sinus diseases by measurement of inflammatory mediators. Allergy 2006,61(11):1280–9.CrossRefPubMed Van Zele T, Claeys S, Gevaert P, Van Maele G, Holtappels G, Van Cauwenberge P, Bachert C: Differentiation of chronic sinus diseases by measurement of inflammatory mediators. Allergy 2006,61(11):1280–9.CrossRefPubMed
5.
go back to reference Bacchetta R, Gambineri E, Roncarolo MG: Role of regulatory T cells and FOXP3 in human diseases. J Allergy Clin Immunol 2007,120(2):227–35.CrossRefPubMed Bacchetta R, Gambineri E, Roncarolo MG: Role of regulatory T cells and FOXP3 in human diseases. J Allergy Clin Immunol 2007,120(2):227–35.CrossRefPubMed
6.
7.
go back to reference Taams LS, Palmer DB, Akbar AN, Robinson DS, Brown Z, Hawrylowicz CM: Regulatory T cells in human disease and their potential for therapeutic manipulation. Immunology 2006,118(1):1–9.CrossRefPubMedPubMedCentral Taams LS, Palmer DB, Akbar AN, Robinson DS, Brown Z, Hawrylowicz CM: Regulatory T cells in human disease and their potential for therapeutic manipulation. Immunology 2006,118(1):1–9.CrossRefPubMedPubMedCentral
8.
go back to reference Xu G, Mou Z, Jiang H, Cheng L, Shi J, Xu R, Oh Y, Li H: A possible role of CD4+CD25+ T cells as well as transcription factor Foxp3 in the dysregulation of allergic rhinitis. Laryngoscope 2007,117(5):876–80.CrossRefPubMed Xu G, Mou Z, Jiang H, Cheng L, Shi J, Xu R, Oh Y, Li H: A possible role of CD4+CD25+ T cells as well as transcription factor Foxp3 in the dysregulation of allergic rhinitis. Laryngoscope 2007,117(5):876–80.CrossRefPubMed
9.
go back to reference Shi J, Fan Y, Xu R, Zuo K, Cheng L, Xu G, Li H: Characterizing T cells phenotypes in nasal polyps in a Chinese population. J Investig Allergol Clin Immunol 2009, in press. Shi J, Fan Y, Xu R, Zuo K, Cheng L, Xu G, Li H: Characterizing T cells phenotypes in nasal polyps in a Chinese population. J Investig Allergol Clin Immunol 2009, in press.
10.
go back to reference Li HB, Cai KM, Liu Z, Xia JH, Zhang Y, Xu R, Xu G: Foxp3+ T regulatory cells (Tregs) are increased in nasal polyps (NP) after treatment with intranasal steroid. Clin Immunol 2008,129(3):394–400.CrossRefPubMed Li HB, Cai KM, Liu Z, Xia JH, Zhang Y, Xu R, Xu G: Foxp3+ T regulatory cells (Tregs) are increased in nasal polyps (NP) after treatment with intranasal steroid. Clin Immunol 2008,129(3):394–400.CrossRefPubMed
11.
go back to reference Van Bruaene N, Perez-Novo CA, Basinski TM, Van Zele T, Holtappels G, De Ruyck N, Schmidt-Weber C, Akdis C, Van Cauwenberge P, Bachert C, Gevaert P: T-cell regulation in chronic paranasal sinus disease. J Allergy Clin Immunol 2008,121(6):1435–41.CrossRefPubMed Van Bruaene N, Perez-Novo CA, Basinski TM, Van Zele T, Holtappels G, De Ruyck N, Schmidt-Weber C, Akdis C, Van Cauwenberge P, Bachert C, Gevaert P: T-cell regulation in chronic paranasal sinus disease. J Allergy Clin Immunol 2008,121(6):1435–41.CrossRefPubMed
12.
go back to reference Shi HZ, Qin XJ: CD4CD25 regulatory T lymphocytes in allergy and asthma. Allergy 2005,60(8):986–95.CrossRefPubMed Shi HZ, Qin XJ: CD4CD25 regulatory T lymphocytes in allergy and asthma. Allergy 2005,60(8):986–95.CrossRefPubMed
13.
go back to reference Strauss L, Whiteside TL, Knights A, Bergmann C, Knuth A, Zippelius A: Selective survival of naturally occurring human CD4+CD25+Foxp3+ regulatory T cells cultured with rapamycin. J Immunol 2007,178(1):320–9.CrossRefPubMed Strauss L, Whiteside TL, Knights A, Bergmann C, Knuth A, Zippelius A: Selective survival of naturally occurring human CD4+CD25+Foxp3+ regulatory T cells cultured with rapamycin. J Immunol 2007,178(1):320–9.CrossRefPubMed
15.
go back to reference Soliman GA: The mammalian target of rapamycin signaling network and gene regulation. Curr Opin Lipidol 2005,16(3):317–23.CrossRefPubMed Soliman GA: The mammalian target of rapamycin signaling network and gene regulation. Curr Opin Lipidol 2005,16(3):317–23.CrossRefPubMed
16.
go back to reference Song J, Salek-Ardakani S, So T, Croft M: The kinases aurora B and mTOR regulate the G1-S cell cycle progression of T lymphocytes. Nat Immunol 2007,8(1):64–73.CrossRefPubMed Song J, Salek-Ardakani S, So T, Croft M: The kinases aurora B and mTOR regulate the G1-S cell cycle progression of T lymphocytes. Nat Immunol 2007,8(1):64–73.CrossRefPubMed
17.
go back to reference Lund VJ, Kennedy DW: Quantification for staging sinusitis. The Staging and Therapy Group. Ann Otol Rhinol Laryngol 1995,167(Suppl):17–21. Lund VJ, Kennedy DW: Quantification for staging sinusitis. The Staging and Therapy Group. Ann Otol Rhinol Laryngol 1995,167(Suppl):17–21.
18.
go back to reference Lezcano-Meza D, Dávila-Dávila B, Vega-Miranda A, Negrete-García MC, Teran LM: Interleukin (IL)-4 and to a lesser extent either IL-13 or interferon-gamma regulate the production of eotaxin-2/CCL24 in nasal polyps. Allergy 2003,58(10):1011–7.CrossRefPubMed Lezcano-Meza D, Dávila-Dávila B, Vega-Miranda A, Negrete-García MC, Teran LM: Interleukin (IL)-4 and to a lesser extent either IL-13 or interferon-gamma regulate the production of eotaxin-2/CCL24 in nasal polyps. Allergy 2003,58(10):1011–7.CrossRefPubMed
19.
go back to reference Roberts T, Beyers N, Aguirre A, Walzl G: Immunosuppression during active tuberculosis is characterized by decreased interferon- gamma production and CD25 expression with elevated forkhead box P3, transforming growth factor- beta, and interleukin-4 mRNA levels. J Infect Dis 2007,195(6):870–8.CrossRefPubMed Roberts T, Beyers N, Aguirre A, Walzl G: Immunosuppression during active tuberculosis is characterized by decreased interferon- gamma production and CD25 expression with elevated forkhead box P3, transforming growth factor- beta, and interleukin-4 mRNA levels. J Infect Dis 2007,195(6):870–8.CrossRefPubMed
20.
go back to reference Jiang S, Lechler RI: CD4+CD25+ regulatory T-cell therapy for allergy, autoimmune disease and transplant rejection. Inflamm Allergy Drug Targets 2006,5(4):239–42.CrossRefPubMed Jiang S, Lechler RI: CD4+CD25+ regulatory T-cell therapy for allergy, autoimmune disease and transplant rejection. Inflamm Allergy Drug Targets 2006,5(4):239–42.CrossRefPubMed
21.
go back to reference Bernstein JM, Ballow M, Rich G, Allen C, Swanson M, Dmochowski J: Lymphocyte subpopulations and cytokines in nasal polyps: is there a local immune system in the nasal polyp? Otolaryngol Head Neck Surg 2004,130(5):526–35.CrossRefPubMed Bernstein JM, Ballow M, Rich G, Allen C, Swanson M, Dmochowski J: Lymphocyte subpopulations and cytokines in nasal polyps: is there a local immune system in the nasal polyp? Otolaryngol Head Neck Surg 2004,130(5):526–35.CrossRefPubMed
22.
go back to reference Zhang L, Zhao Y: The regulation of Foxp3 expression in regulatory CD4(+) CD25(+)T cells: multiple pathways on the road. J Cell Physiol 2007,211(3):590–7.CrossRefPubMed Zhang L, Zhao Y: The regulation of Foxp3 expression in regulatory CD4(+) CD25(+)T cells: multiple pathways on the road. J Cell Physiol 2007,211(3):590–7.CrossRefPubMed
23.
24.
go back to reference Sauer S, Bruno L, Hertweck A, Finlay D, Leleu M, Spivakov M, Knight ZA, Cobb BS, Cantrell D, O'Connor E, Shokat KM, Fisher AG, Merkenschlager M: T cell receptor signaling controls Foxp3 expression via PI3K, Akt, and mTOR. Proc Natl Acad Sci USA 2008,105(22):7797–802.CrossRefPubMedPubMedCentral Sauer S, Bruno L, Hertweck A, Finlay D, Leleu M, Spivakov M, Knight ZA, Cobb BS, Cantrell D, O'Connor E, Shokat KM, Fisher AG, Merkenschlager M: T cell receptor signaling controls Foxp3 expression via PI3K, Akt, and mTOR. Proc Natl Acad Sci USA 2008,105(22):7797–802.CrossRefPubMedPubMedCentral
25.
go back to reference Strauss L, Whiteside TL, Knights A, Bergmann C, Knuth A, Zippelius A: Selective survival of naturally occurring human CD4+CD25+Foxp3+ regulatory T cells cultured with rapamycin. J Immunol 2007,178(1):320–9.CrossRefPubMed Strauss L, Whiteside TL, Knights A, Bergmann C, Knuth A, Zippelius A: Selective survival of naturally occurring human CD4+CD25+Foxp3+ regulatory T cells cultured with rapamycin. J Immunol 2007,178(1):320–9.CrossRefPubMed
26.
go back to reference Battaglia M, Stabilini A, Migliavacca B, Horejs-Hoeck J, Kaupper T, Roncarolo MG: Rapamycin promotes expansion of functional CD4+CD25+FOXP3+ regulatory T cells of both healthy subjects and type 1 diabetic patients. J Immunol 2006,177(12):8338–47.CrossRefPubMed Battaglia M, Stabilini A, Migliavacca B, Horejs-Hoeck J, Kaupper T, Roncarolo MG: Rapamycin promotes expansion of functional CD4+CD25+FOXP3+ regulatory T cells of both healthy subjects and type 1 diabetic patients. J Immunol 2006,177(12):8338–47.CrossRefPubMed
27.
go back to reference Kang J, Huddleston SJ, Fraser JM, Khoruts A: De novo induction of antigen-specific CD4+CD25+Foxp3+ regulatory T cells in vivo following systemic antigen administration accompanied by blockade of mTOR. J Leukoc Biol 2008,83(5):1230–9.CrossRefPubMed Kang J, Huddleston SJ, Fraser JM, Khoruts A: De novo induction of antigen-specific CD4+CD25+Foxp3+ regulatory T cells in vivo following systemic antigen administration accompanied by blockade of mTOR. J Leukoc Biol 2008,83(5):1230–9.CrossRefPubMed
28.
go back to reference Xia ZW, Xu LQ, Zhong WW, Wei JJ, Li NL, Shao J, Li YZ, Yu SC, Zhang ZL, et al.: Heme oxygenase-1 attenuates ovalbumin-induced airway inflammation by up-regulation of foxp3 T-regulatory cells, interleukin-10, and membrane-bound transforming growth factor- 1. Am J Pathol 2007,171(6):1904–14.CrossRefPubMedPubMedCentral Xia ZW, Xu LQ, Zhong WW, Wei JJ, Li NL, Shao J, Li YZ, Yu SC, Zhang ZL, et al.: Heme oxygenase-1 attenuates ovalbumin-induced airway inflammation by up-regulation of foxp3 T-regulatory cells, interleukin-10, and membrane-bound transforming growth factor- 1. Am J Pathol 2007,171(6):1904–14.CrossRefPubMedPubMedCentral
Metadata
Title
Activated mammalian target of rapamycin is associated with T regulatory cell insufficiency in nasal polyps
Authors
Geng Xu
Jiahong Xia
Xiaoyang Hua
Han Zhou
Chuanzhao Yu
Zheng Liu
Kemin Cai
Jianbo Shi
Huabin Li
Publication date
01-12-2009
Publisher
BioMed Central
Published in
Respiratory Research / Issue 1/2009
Electronic ISSN: 1465-993X
DOI
https://doi.org/10.1186/1465-9921-10-13

Other articles of this Issue 1/2009

Respiratory Research 1/2009 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.